Abstracts tagged "Cohort Study"

Abstract Number: 2607 • ACR Convergence 2025
ERS-RA as a Tool for Cardiovascular Risk Prediction in Established Rheumatoid Arthritis: An External Validation
Misti Paudel¹, Katherine Liao², Jon Giles³, Joan Bathon⁴, Hongshu Guan⁵, Brendan Everett⁶, Leah Santacroce⁷, Nancy Shadick⁸, Michael Weinblatt⁹, Pamela Rist⁶ and Daniel Solomon¹⁰, ¹Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ²Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital, Boston, MA, USA, Boston, MA, ³Cedars Sinai Medical Center, Los Angeles, CA, ⁴Columbia University, NEW YORK, NY, ⁵Brigham and Women's Hospital/ Harvard Medical School, Boston, ⁶Brigham and Women's Hospital and Harvard Medical School, Boston, ⁷Brigham and Women's Hospital, Boston, MA, ⁸Brigham & Women's Hospital, Boston, MA, ⁹Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, ¹⁰Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA
Background/Purpose: The Expanded Risk Model for Rheumatoid Arthritis (ERS-RA) incorporates traditional CV risk factors and RA-related measures of disease activity and has demonstrated better performance…
Abstract Number: 2349 • ACR Convergence 2025
Classification of “Difficult-to-Manage Axial Spondyloarthritis”: A Real-World Cohort Study Evaluating the ASAS 2024 Criteria Over Time
Gözde Sevgi Kart bayram¹, Muhammed Çağrı Akdemir², Mustafa Ekici³, Gizem Ayan⁴, Büşra Fırlatan Yazgan¹, Erdinç Ünaldı³, Buğu Bulat¹, Ali Aytuğ Kuştaş³, Ali Akdoğan⁵, Omer Karadağ⁵, Şule Apraş Bilgen¹, Ali İhsan Ertenli¹, Sedat Kiraz³, Umut Kalyoncu¹ and Levent Kılıç¹, ¹Division of Rheumatology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey, Ankara, Turkey, ²Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Ankara, Turkey, Ankara, Turkey, ³Division of Rheumatology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey, Ankara, Ankara, Turkey, ⁴Ankara Research and Training Hospital, Ankara, Turkey, ⁵Division of Rheumatology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey, Ankara
Background/Purpose: The concept of difficult-to-manage axial spondyloarthritis (D2M-axSpA)[1], may vary over time. Transitions between D2M and non-D2M classifications throughout the disease course remain unclear. This…
Abstract Number: 2060 • ACR Convergence 2025
Treatment Patterns And Drug Use In Idiopathic Inflammatory Myopathies. Description Of The First Year After Diagnosis In A Swedish Myositis Cohort.
Irene Peralta-García¹, Naz Haque², Dag Leonard³, Anna Glasin⁴, Silva Puksic⁵, Balsam Hanna⁶, My Axelhed⁷, Theodoros Lappas⁵, Farbicio Espinosa Ortega¹, Karin Lodin¹, NIls Eckerdal², Helene Alexanderson⁸, Elizabeth Hsia⁹, Federico Zazzetti¹⁰, Ingrid Lundberg¹¹ and Marie Holmqvist¹, ¹Karolinska Institutet, Clinical Epidemiology Division, Department of Medicine Solna. Karolinska University Hospital, Medical Unit of Gastroenterology, Dermatology, Rheumatology. Theme Inflammation and Ageing, Stockholm, Sweden, ²Karolinska Institutet, Clinical Epidemiology Division, Department of Medicine Solna, Stockholm, Sweden, ³Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ⁴Rheumatology Department, Linköping Hospital, LInköping, Sweden, ⁵Rheumatology Department, Örebro University Hospital, Örebro, Sweden, ⁶Rheumatology Department, Sahlgrenska University Hospital, Gothenburg, Sweden, ⁷Rheumatology Department, Västmanlands Hospital, Västerås, Sweden, ⁸Karolinska University Hospital, Stockholm, Sweden, ⁹Johnson & Johnson, Spring House, PA, ¹⁰Johnson & Johnson, Horsham, PA, USA, Ambler, PA, ¹¹Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Due to the rarity and heterogeneity of idiopathic inflammatory myopathies (IIM), we lack robust randomized trials to guide treatment decisions. Most of current practice…
Abstract Number: 1747 • ACR Convergence 2025
Risk of serious infection in patients with rheumatoid arthritis-associated interstitial lung disease or bronchiectasis: A matched cohort study
QIANRU ZHANG¹, Ying Qi², Xiaosong Wang³, Gregory McDermott⁴, Sung Hae Chang⁵, Mark Chaballa⁶, Vadim Khaychuk⁷, Misti Paudel⁸ and Jeffrey Sparks⁹, ¹Brigham and Women’s Hospital/Beijing Tsinghua Changgung Hospital, Cambridge, MA, ²Brigham and Women’s Hospital, Boston, ³Brigham and Women's Hospital, Natick, MA, ⁴Brigham and Women's Hospital, Brookline, MA, ⁵Soonchunhyang University College of Medicine, Cheonan, MA, South Korea, ⁶Bristol Myers Squibb, Princeton, NJ, ⁷Bristol Myers Squibb, Pennington, NJ, ⁸Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ⁹Brigham and Women's Hospital, Boston, MA
Background/Purpose: RA-associated lung disease (RA-LD), including RA-associated interstitial lung disease (RA-ILD) and RA-associated bronchiectasis (RA-BR), contributes significantly to morbidity and mortality in RA patients. RA…
Abstract Number: 1534 • ACR Convergence 2025
Rapid Oral Glucocorticoid Discontinuation or Dose Reduction Among US Patients with SLE Receiving Belimumab in a Real-World Setting
Yan Chen¹, Maral DerSarkissian¹, Shumin Rui¹, Justin Clark¹, Daniel Moldaver², Jeffrey J. Ellis³, Karen Worley³ and Aarat M Patel⁴, ¹Analysis Group, Los Angeles, CA, ²GSK, Global Real-World Evidence & Health Outcomes Research, Toronto, ON, Canada, ³GSK, Global Real-World Evidence & Health Outcomes Research, Collegeville, PA, ⁴GSK, US Medical Affairs, Durham, NC
Background/Purpose: Belimumab (BEL), a B-cell modulator mAb that selectively inhibits soluble B-lymphocyte stimulator and reduces autoreactive B cells that drive lupus disease activity, is approved…
Abstract Number: 1255 • ACR Convergence 2025
Lung Transplantation Outcomes for Pulmonary Sarcoidosis Compared to Idiopathic Pulmonary Fibrosis: A Single Institution Multisite Experience
Reena Yaman¹, Lisa Balistreri², Maximiliano Diaz Menindez³, Sehreen Mumtaz¹, Megan Sullivan³, Alexander Hochwald¹ and Florentina Berianu¹, ¹Mayo Clinic Florida, Jacksonville, FL, ²Lee Health, Cape Coral, FL, ³Mayo Clinic Arizona, Scottsdale, AZ
Background/Purpose: Pulmonary disease is present in most sarcoidosis cases with up to 10% of patients progressing to advanced lung disease.1 Pulmonary sarcoidosis accounted for 2.5%…
Abstract Number: 1048 • ACR Convergence 2025
Impact of Hydroxychloroquine Usage on QTc in Veterans with Rheumatic Musculoskeletal Disease
Malika Ibrahim¹, Samuel Good², Victor Tran³, David Chetrit⁴, Michael McClean⁵, Myung Shin Sim⁶, Hannah Kang¹, Jennifer Barton⁷, Meika Fang⁸, Angelo Gaffo⁹, fadi Hage¹⁰, cynthia Jackevicius⁵, Michael Pillinger¹¹, gabriela Schmajuk¹², Jasvinder Singh¹³, Alberta Warner¹⁴, Neal Yaun¹⁵ and John FitzGerald¹⁶, ¹David Geffen School of Medicine at University of California, Los Angeles, Department of Medicine, Los Angeles, CA, ²David Geffen School of Medicine at University of California, Los Angeles, Department of Medicine, Division of Rheumatology, Los Angeles, CA, ³David Geffen School of Medicine at University of California, Los Angeles, Department of Medicine, Costa Mesa, CA, ⁴Carolina Health Specialists, Myrtle Beach, SC, ⁵Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, ⁶West LA VA Medical Center, Los Angeles, ⁷VA Portland Health Care System/OHSU, Portland, OR, ⁸VA Greater Los Angeles/UCLA, Los Angeles, CA, ⁹Division of Rheumatology and Clinical Immunology, University of Alabama, Birmingham, AL, USA; Birmingham VA Medical Center, Birmingham, AL, USA, Birmingham, AL, ¹⁰VA Birmingham health care, Birmingham, AL, ¹¹New York University Grossman School of Medicine, New York,, NY, ¹²University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA, ¹³Baylor College of Medicine, Houston, TX, ¹⁴VA Greater Los Angeles/UCLA, Los Angeles, ¹⁵UCSF / SFVA, San Francisco, ¹⁶UCLA, Los Angeles, CA
Background/Purpose: Hydroxychloroquine (HCQ) is widely used for rheumatic diseases, but data on its cardiac safety, particularly QTc prolongation, remains limited. Concerns about HCQ inducing QTc…
Abstract Number: 0547 • ACR Convergence 2025
Determinants of Difficult-to-Manage Axial Spondyloarthritis: Results from a Prospective Cohort Study
Patricia Remalante-Rayco¹, Laura Passalent², Manal Alnasser³, Tina Chim¹, Robert Inman¹, Nigil Haroon⁴ and Denis Poddubnyy⁵, ¹University Health Network, Toronto, ON, Canada, ²Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ³King Abdulaziz Medical City, Riyadh, Saudi Arabia, ⁴Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada, ⁵Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany
Background/Purpose: The Assessment of SpondyloArthritis international Society (ASAS) group has recently introduced a consensus-based definition for difficult-to-manage (D2M) axial spondyloarthritis (axSpA) to identify patients with…
Abstract Number: 0318 • ACR Convergence 2025
Plasma Lipoprotein Subclasses and Risk of Incident Knee Osteoarthritis: A Population-Based Cohort Study
Cheng Li¹, Jing wu², Yuqing Zhang³, Hongyi He⁴, Ying Hu⁵, Jie Wei⁶, Guanghua Lei⁶ and Chao Zeng⁶, ¹Xiangya Hospital, Changsha, China (People's Republic), ²Xiangya Hospital, chagnsha, Hunan, China (People's Republic), ³Massachusetts General Hospital, Quincy, MA, ⁴Xiangya Hospital Central South University, Changsha, China (People's Republic), ⁵Xiangya School of Public Health Central South University, changsha, China (People's Republic), ⁶Xiangya Hospital, Central South University, Changsha, Hunan, China (People's Republic)
Background/Purpose: Lipoprotein subclasses play diverse roles in health and disease. Although lipoproteins have been implicated in knee osteoarthritis (KOA), the relationship between lipoprotein subclasses and…
Abstract Number: 2606 • ACR Convergence 2025
The Impact of Social Media and Artificial Intelligence on Illness Perception and Treatment Adherence in Patients with Rheumatic Diseases
Egla Samantha Sanchez-Peralta¹, Pablo Gamez-Siller¹, Angel Kevin Garza-Elizondo¹, Fabiola Alejandra Fuentes-Rios¹, Gemma Alely Garcia-Ramos¹, Derek de Jesus Gauna Leal¹, Ariana Silva-de Leon¹, Nathalia Valdez-Benavides¹, Jesus Alberto Cardenas-de la Garza², Margarita Isabel Alarcon-Jarquin³, Dionicio A. Galarza-Delgado⁴ and Diana E. Flores-Alvarado¹, ¹Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Nuevo Leon, Mexico, ²Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Mexico, ³Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ⁴Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico
Background/Purpose: Social media (SM) and Artificial Intelligence (AI) are common sources of health information for patients with chronic diseases. Seeking medical information from unreliable sources…
Abstract Number: 2338 • ACR Convergence 2025
Real-World Outcomes of Combined Tofacitinib and TNF Inhibitor Therapy in Refractory Inflammatory Arthritis: A Tertiary Care Experience from India
Aashish Agrawal and Balakrishnan Canchi, Hinduja Hospital, Mumbai, Maharashtra, India
Background/Purpose: The use of combination biologic and targeted synthetic DMARDs remains controversial due to safety concerns, yet may offer benefit in refractory inflammatory arthritis. This…
Abstract Number: 2054 • ACR Convergence 2025
A Changing Paradigm: Reassessing the Role of Muscle Biopsy in Idiopathic Inflammatory Myopathies in a Single-Center Cohort
Ami Purohit¹, Najia Shakoor², Dmitriy Cherny¹ and Juan Schmukler¹, ¹Rush University Medical Center, Chicago, IL, ²Rush University, Chicago, IL
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) encompass a heterogenous group of autoimmune diseases characterized by inflammation of muscle and other target organs. Muscle biopsy was historically…
Abstract Number: 1721 • ACR Convergence 2025
Excess Mortality in SLE Is Concentrated in Lupus Nephritis and aPL-Positive Subsets: A population-based inception cohort study
Mario Bautista-Vargas¹, Erika Navarro-Mendoza¹, Jaime Flores-Gouyonnet¹, Ali Ardekani¹, Maria Cuellar-Gutierrez¹, Gabriel Figueroa-Parra², Mariana Gonzalez-Treviño³, Jose Antonio Meade-Aguilar⁴, Alain Sanchez-Rodriguez⁵, Andrew C. Hanson¹, Cassondra Hulshizer⁶, Cynthia Crowson⁷ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, ³Vanderbilt University Medical Center, Nashville, TN, ⁴Boston University/Boston Medical Center, Boston, MA, ⁵ABC Medical Center, Ciudad de México, Federal District, Mexico, ⁶Mayo Clinic, Rochester, ⁷Mayo Clinic, Stewartvillle, MN
Background/Purpose: Five-year survival in SLE has plateaued since the 1990s. Most epidemiologic studies pool all SLE phenotypes; It is possible that the excess mortality observed…
Abstract Number: 1533 • ACR Convergence 2025
Belimumab Is Associated with Early Improvement in Disease Activity Measures Among Patients with Systemic Lupus Erythematosus in the US
Yan Chen¹, Maral DerSarkissian¹, Shumin Rui¹, Justin Clark¹, Daniel Moldaver², Jeffrey J. Ellis³, Karen Worley³ and Aarat M Patel⁴, ¹Analysis Group, Los Angeles, CA, ²GSK, Global Real-World Evidence & Health Outcomes Research, Toronto, ON, Canada, ³GSK, Global Real-World Evidence & Health Outcomes Research, Collegeville, PA, ⁴GSK, US Medical Affairs, Durham, NC
Background/Purpose: Belimumab (BEL), a B-cell modulator mAb that selectively inhibits soluble B-lymphocyte stimulator and reduces autoreactive B cells that drive lupus disease activity, is approved…
Abstract Number: 1220 • ACR Convergence 2025
Predictors of Progressive Pulmonary Fibrosis in Idiopathic Inflammatory Myopathies : a Retrospective Study of 502 Cases
Wei Bian¹, Jian Hao¹, Na zhang¹, Xiaojing Zhang¹, Fumin Qi¹, Yin Zhao² and Wei Wei¹, ¹Tianjin Medical University General Hospital, Tianjin, China (People's Republic), ²Affiliated Hospital of Yunnan University, Yunnan, China (People's Republic)
Background/Purpose: Interstitial lung disease (ILD) in idiopathic inflammatory myopathies (IIM) causes worse prognosis. Some patients develop progressive pulmonary fibrosis (PPF) despite appropriate treatment. Identifying predictors…

1
2
3
…
38
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].